Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-Based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS).

Next Previous
Search
Trial Profile

A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-Based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin; Ifosfamide
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Clear cell sarcoma; Endometrial cancer; Malignant fibrous histiocytoma; Myxoid liposarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development; PharmaMar

    • Most Recent Events

    • 21 Nov 2014 Post hoc analysis of BRCA1 protein expression influence on trabectedin and doxorubicin efficacy presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 07 Feb 2014 Results published in the European Journal of Cancer.
    • 04 Jun 2013 Interim results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top